Neomed Institute:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Neomed Institute - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9427
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:カナダ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Neomed Institute (Neomed) is a not-for-profit organization that provides drug discovery and development services. The organization spans its expertise in the development of small molecule therapeutics, biologics and vaccines. It offers chemistry, DMPK, fermentation and biology laboratories, decontamination & sterilization facilities, analytical and open-access NMR services. Neomed offers programs such as GPR120, for diabetes and metabolic disorder; NEO5937 for treatment of pain and respiratory indications; BRD4 for leukemia and breast cancers and others. The organization carries out research and development in partnership with The Institute for Research in Immunology and cancer commercialization of research, mitacs, Crocus Laboratories and epigeneti among others. Neomed is headquartered in Montreal, Quebec, Canada.

Neomed Institute – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Neomed Institute, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Neomed Institute, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Neomed Institute, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Neomed Institute, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Neomed Institute, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Neomed Institute, Pharmaceuticals & Healthcare, Deal Details 10
Private Equity 10
Ampersand Capital Partners Invests NEOMED-LABS from NEOMED Institute 10
Partnerships 11
Axxam Partners with Neomed Institute 11
Neomed Institute Partners with McGill University 12
Univalor Partners with Centre de recherche du Centre hospitalier de l’Universite de Montreal and Neomed Institute 13
Epigenetix Partners with Neomed Institute 14
Licensing Agreements 15
Artelo Biosciences to Enter into Licensing Agreement with Neomed Institute 15
BELLUS Health Enters into Licensing Agreement with NEOMED Institute for BLU-5937 16
Neomed Institute – Key Competitors 17
Neomed Institute – Key Employees 18
Neomed Institute – Locations And Subsidiaries 19
Head Office 19
Other Locations & Subsidiaries 19
Recent Developments 20
Product News 20
04/27/2017: BELLUS Health to present at Bloom Burton & Co. Healthcare Investor Conference 20
Clinical Trials 21
Sep 18, 2017: BELLUS Health’s BLU-5937 Significantly Reduces Cough Without Taste Disturbance in Two Preclinical Models 21
Other Significant Developments 23
Sep 04, 2018: Ampersand invests in management buyout of clinical immunology provider NEOMED-LABS from the NEOMED Institute 23
Jun 05, 2018: Pfizer Canada Invests in the NEOMED Institute to Further Support Growth in Quebec’s Life Sciences Sector 24
Appendix 25
Methodology 25
About GlobalData 25
Contact Us 25
Disclaimer 25

List of Tables
Neomed Institute, Pharmaceuticals & Healthcare, Key Facts 2
Neomed Institute, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Neomed Institute, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Neomed Institute, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Neomed Institute, Deals By Therapy Area, 2012 to YTD 2018 8
Neomed Institute, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Ampersand Capital Partners Invests NEOMED-LABS from NEOMED Institute 10
Axxam Partners with Neomed Institute 11
Neomed Institute Partners with McGill University 12
Univalor Partners with Centre de recherche du Centre hospitalier de l'Universite de Montreal and Neomed Institute 13
Epigenetix Partners with Neomed Institute 14
Artelo Biosciences to Enter into Licensing Agreement with Neomed Institute 15
BELLUS Health Enters into Licensing Agreement with NEOMED Institute for BLU-5937 16
Neomed Institute, Key Competitors 17
Neomed Institute, Key Employees 18
Neomed Institute, Other Locations 19

List of Figures
Neomed Institute, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Neomed Institute, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Neomed Institute, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Neomed Institute, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Neomed Institute, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Neomed Institute, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Neomed Institute, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Neomed Institute, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Neomed Institute:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Kone Corporation
    Kone Corporation - Strategy, SWOT and Corporate Finance Report Summary Kone Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Occidental Chemical Corporation:企業の戦略的SWOT分析
    Occidental Chemical Corporation - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pro …
  • Downer EDI Ltd (DOW)-エネルギー分野:企業M&A・提携分析
    Summary Downer EDI Limited (Downer) is a diversified services company. The company offers wide range of services such as transport infrastructure, engineering, utility, construction, and maintenance., It also provides mining services such as open-cut mining, crushing, underground mining operations, …
  • Escher Group Holdings plc:企業の戦略・SWOT・財務情報
    Escher Group Holdings plc - Strategy, SWOT and Corporate Finance Report Summary Escher Group Holdings plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • SRI International:医療機器:M&Aディール及び事業提携情報
    Summary SRI International (SRI) is a non-profit organization that provides commercial research and development programs. The organization’s services include research and development, innovation consulting, technology solutions, bioscience contract research, specialized facilities and services. It pe …
  • SGL Carbon SE (SGL):企業の財務・戦略的SWOT分析
    SGL Carbon SE (SGL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Prescient Therapeutics Ltd (PTX):企業の財務・戦略的SWOT分析
    Summary Prescient Therapeutics Ltd (Prescient Therapeutics), formerly Virax Holdings Ltd, is a biotechnology company which develops novel medicines for cancer treatment. The company is investigating OmniCAR, an immune receptor platform that controls T-cell activity and multi-antigen targeting with a …
  • Edwards Lifesciences Corp (EW):企業の財務・戦略的SWOT分析
    Edwards Lifesciences Corp (EW) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • PTT Exploration and Production Public Co Ltd (PTTEP):企業の財務・戦略的SWOT分析
    PTT Exploration and Production Public Co Ltd (PTTEP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s k …
  • Concord Medical Services Holdings Ltd (CCM):企業の財務・戦略的SWOT分析
    Summary Concord Medical Services Holdings Ltd (CMS) is a diagnostic imaging center that offers clinical support services and laboratory services. The center offers radiotherapy and diagnostic imaging equipment services such as head gamma knife systems, body gamma knife systems and linear accelerator …
  • Lassila & Tikanoja plc:企業のM&A・事業提携・投資動向
    Lassila & Tikanoja plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Lassila & Tikanoja plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions …
  • Taghleef Industries L.L.C.:企業の戦略・SWOT・財務分析
    Taghleef Industries L.L.C. - Strategy, SWOT and Corporate Finance Report Summary Taghleef Industries L.L.C. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Royal DSM N.V.:企業のM&A・事業提携・投資動向
    Royal DSM N.V. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Royal DSM N.V. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestmen …
  • Callidus Software Inc (CALD):企業の財務・戦略的SWOT分析
    Summary Callidus Software Inc (Callidus) a subsidiary of SAP SE, operates as a technology company that offers a cloud-based customer relationship management (CRM) solutions. The company’s product portfolio includes contract life cycle management (CLM), configure price quote (CPQ) solutions, clicktoo …
  • Airasia Group Berhad
    Airasia Group Berhad - Strategy, SWOT and Corporate Finance Report Summary Airasia Group Berhad - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Essar Power Limited:企業の発電所・SWOT分析2018
    Essar Power Limited - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees …
  • Washington University in St Louis:製薬・医療:M&Aディール及び事業提携情報
    Summary Washington University in St Louis (WUSTL), a subsidiary of University of Washington is an educational university which provides education and research services. The university provides various courses of bachelor’s, master’s, and doctoral degrees in a wide range of traditional and interdisci …
  • First Republic Bank:企業のM&A・事業提携・投資動向
    First Republic Bank - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's First Republic Bank Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), …
  • Tahoe Resources Inc.:企業の戦略・SWOT・財務情報
    Tahoe Resources Inc. - Strategy, SWOT and Corporate Finance Report Summary Tahoe Resources Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • HemaCare Corp (HEMA):企業の財務・戦略的SWOT分析
    Summary HemaCare Corp (HemaCare) is a provider of biological blood products and services. The company offers primary blood cells and tissues derived from normal and mobilized peripheral blood, cord blood, and bone marrow. It spans its expertise in isolations, custom cell collections and testing of p …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆